Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS)
- Previous Close
26.72 - Open
26.69 - Bid 26.74 x --
- Ask 26.75 x --
- Day's Range
26.57 - 26.93 - 52 Week Range
23.85 - 40.78 - Volume
4,034,146 - Avg. Volume
6,110,236 - Market Cap (intraday)
24.656B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
11.53 - EPS (TTM)
2.32 - Earnings Date Apr 26, 2025
- Forward Dividend & Yield 1.30 (4.87%)
- Ex-Dividend Date Jun 17, 2024
- 1y Target Est
--
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, neurology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. The company was formerly known as Hubei Hongcheng General Machinery Co., Ltd and changed its name to Hubei Jumpcan Pharmaceutical Co., Ltd. in March 2015. Hubei Jumpcan Pharmaceutical Co., Ltd. is based in Taixing, China. Hubei Jumpcan Pharmaceutical Co., Ltd. operates as a subsidiary of Jiangsu Jichuan Holding Group Co., Ltd.
www.jumpcan.com5,026
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600566.SS
View MorePerformance Overview: 600566.SS
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600566.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600566.SS
View MoreValuation Measures
Market Cap
24.63B
Enterprise Value
12.67B
Trailing P/E
11.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.43
Price/Book (mrq)
1.63
Enterprise Value/Revenue
1.77
Enterprise Value/EBITDA
5.02
Financial Highlights
Profitability and Income Statement
Profit Margin
29.79%
Return on Assets (ttm)
6.95%
Return on Equity (ttm)
14.51%
Revenue (ttm)
7.14B
Net Income Avi to Common (ttm)
2.13B
Diluted EPS (ttm)
2.32
Balance Sheet and Cash Flow
Total Cash (mrq)
12.58B
Total Debt/Equity (mrq)
4.58%
Levered Free Cash Flow (ttm)
1.12B